AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

NMPA has granted conditional approval for Hutchmed’s Tazverik to treat adults with relapsed or refractory (R/R) follicular ...

Beijing's healthcare industry surpassed 1.06 trillion yuan ($146.2 billion) in scale in 2024, marking an 8.7% year-on-year increase and making it the first city in China to reach this milestone, ...

A European business lobby group urged China to take steps not to prioritise low prices over product safety in the country's ...

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic drug supplies.

What more should China do to create a more enabling business environment for foreign investors? MOREL: As China approaches ...

China issued the final version of its compliance guidelines for health care companies to prevent commercial bribery ...

Full Year 2024 Results Key Financial Results Revenue: US$630.2m (down 25% from FY ...

The development is set to make India less reliant on China for imports of raw material used by the pharmaceutical industry.